Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
In a significant milestone for cancer research, the ECOG-ACRIN Cancer Research Group has announced the completion of patient enrollment in ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine